1. systolic blood pressure \<100 mmhg. 2. systolic blood pressure \> 180 mmhg or \>160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. 3. diastolic blood pressure \> 110 mmhg 4. known history of heart failure with reduced ejection fraction (ef \<40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). 5. serum k\>5.0 meq/l on admission. 6. known pregnancy or breastfeeding. 7. egfr \<30 ml/min/1.73m2 8. \>50% increase in creatinine (to a creatinine \>1.5 mg/dl) compared to most recent creatinine in the past six months, if available 9. urine protein-to-creatitine ratio \> 3 g/g or proteinuria \> 3 g/24-hours within the past year 10. ongoing treatment with aliskiren or sacubitril-valsartan. 11. inability to obtain informed consent from patient. 12. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.

1. systolic blood pressure \<100 mmhg. 2. systolic blood pressure \> 180 mmhg or \>160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. 3. diastolic blood pressure \> 110 mmhg 4. known history of heart failure with reduced ejection fraction (ef \<40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). 5. serum k\>5.0 meq/l on admission. 6. known pregnancy or breastfeeding. 7. egfr \<30 ml/min/1.73m2 8. \>50% increase in creatinine (to a creatinine \>1.5 mg/dl) compared to most recent creatinine in the past six months, if available 9. urine protein-to-creatitine ratio \> 3 g/g or proteinuria \> 3 g/24-hours within the past year 10. ongoing treatment with aliskiren or sacubitril-valsartan. 11. inability to obtain informed consent from patient. 12. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.

systolic blood pressure <100 mmhg. systolic blood pressure > 180 mmhg or >160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. diastolic blood pressure > 110 mmhg known history of heart failure with reduced ejection fraction (ef <40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). serum k>5.0 meq/l on admission. known pregnancy or breastfeeding. egfr <30 ml/min/1.73m2 >50% increase in creatinine (to a creatinine >1.5 mg/dl) compared to most recent creatinine in the past six months, if available urine protein-to-creatitine ratio > 3 g/g or proteinuria > 3 g/24-hours within the past year ongoing treatment with aliskiren or sacubitril-valsartan. inability to obtain informed consent from patient. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.

systolic blood pressure <100 mmhg. systolic blood pressure > 180 mmhg or >160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. diastolic blood pressure > 110 mmhg known history of heart failure with reduced ejection fraction (ef <40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). serum k>5.0 meq/l on admission. known pregnancy or breastfeeding. egfr <30 ml/min/1.73m2 >50% increase in creatinine (to a creatinine >1.5 mg/dl) compared to most recent creatinine in the past six months, if available urine protein-to-creatitine ratio > 3 g/g or proteinuria > 3 g/24-hours within the past year ongoing treatment with aliskiren or sacubitril-valsartan. inability to obtain informed consent from patient. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.

1. systolic blood pressure <100 mmhg. 2. systolic blood pressure > 180 mmhg or >160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. 3. diastolic blood pressure > 110 mmhg 4. known history of heart failure with reduced ejection fraction (ef <40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). 5. serum k>5.0 meq/l on admission. 6. known pregnancy or breastfeeding. 7. egfr <30 ml/min/1.73m2 8. >50% increase in creatinine (to a creatinine >1.5 mg/dl) compared to most recent creatinine in the past six months, if available 9. urine protein-to-creatitine ratio > 3 g/g or proteinuria > 3 g/24-hours within the past year 10. ongoing treatment with aliskiren or sacubitril-valsartan. 11. inability to obtain informed consent from patient. 12. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.

1. systolic blood pressure <100 mmhg. 2. systolic blood pressure > 180 mmhg or >160 if unable to substitute aceis/arbs for another antihypertensive class, per the investigator's discretion. 3. diastolic blood pressure > 110 mmhg 4. known history of heart failure with reduced ejection fraction (ef <40%) on their most recent echo and/or clinical heart failure with unknown ef (i.e. no echo in approximately the past year). 5. serum k>5.0 meq/l on admission. 6. known pregnancy or breastfeeding. 7. egfr <30 ml/min/1.73m2 8. >50% increase in creatinine (to a creatinine >1.5 mg/dl) compared to most recent creatinine in the past six months, if available 9. urine protein-to-creatitine ratio > 3 g/g or proteinuria > 3 g/24-hours within the past year 10. ongoing treatment with aliskiren or sacubitril-valsartan. 11. inability to obtain informed consent from patient. 12. inability to read and write or lack of access to a smart phone, computer or tablet device at the time of evaluation.